Cite
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.
MLA
Gandhi, Nilay M., et al. “Gemcitabine and Cisplatin Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Carcinoma: Predicting Response and Assessing Outcomes.” Urologic Oncology, vol. 33, no. 5, May 2015, p. 204.e1-204.e7. EBSCOhost, https://doi.org/10.1016/j.urolonc.2015.02.011.
APA
Gandhi, N. M., Baras, A., Munari, E., Faraj, S., Reis, L. O., Liu, J.-J., Kates, M., Hoque, M. O., Berman, D., Hahn, N. M., Eisenberger, M., Netto, G. J., Schoenberg, M. P., & Bivalacqua, T. J. (2015). Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urologic Oncology, 33(5), 204.e1-204.e7. https://doi.org/10.1016/j.urolonc.2015.02.011
Chicago
Gandhi, Nilay M., Alexander Baras, Enrico Munari, Sheila Faraj, Leonardo O. Reis, Jen-Jane Liu, Max Kates, et al. 2015. “Gemcitabine and Cisplatin Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Carcinoma: Predicting Response and Assessing Outcomes.” Urologic Oncology 33 (5): 204.e1-204.e7. doi:10.1016/j.urolonc.2015.02.011.